NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a ...
NMD Pharma has reported phase 1/2a data on its myasthenia gravis candidate, furthering its efforts to treat an aspect of the disease that it thinks therapies from AstraZeneca, argenx, Johnson & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback